The Experts below are selected from a list of 27852 Experts worldwide ranked by ideXlab platform
J E Meyer - One of the best experts on this subject based on the ideXlab platform.
-
atypical Ductal hyperplasia and Ductal Carcinoma in situ as revealed by large core needle breast biopsy results of surgical excision
American Journal of Roentgenology, 2000Co-Authors: Marla Rosenfield L Darling, Carolyn M Kaelin, Susan V. Lester, Darrell N Smith, Donnalee G Selland, C M Denison, Pamela J Dipiro, David I Rose, Esther Rhei, J E MeyerAbstract:OBJECTIVE: This investigation compares the frequency of histologic underestimation of breast Carcinoma that occurs when a large-core needle biopsy reveals atypical Ductal hyperplasia or Ductal Carcinoma in situ with the automated 14-gauge needle, the 14-gauge directional vacuum-assisted biopsy device, and the 11-gauge directional vacuum-assisted biopsy device. SUBJECTS AND METHODS: Evaluation of 428 large-core needle biopsies yielding atypical Ductal hyperplasia (139 lesions) or Ductal Carcinoma in situ (289 lesions) was performed. The results of subsequent surgical excision were retrospectively compared with the needle biopsy results. RESULTS: For lesions initially diagnosed as Ductal Carcinoma in situ, underestimation of invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device when compared with the automated 14-gauge needle (10% versus 21%, p 0.1). For lesions diagnosed initially as atypical Ductal hyperplasia, underestimation of Ductal Carcinoma in situ and invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device compared with the 14-gauge directional vacuum-assisted device (19% versus 39%, p = 0. 025) and with the automated 14-gauge needle (19% versus 44%, p = 0. 01). CONCLUSION: The frequency of histologic underestimation of breast Carcinoma in lesions initially diagnosed as atypical Ductal hyperplasia or Ductal Carcinoma in situ using large-core needle biopsy is substantially lower with the 11-gauge directional vacuum-assisted device than with the automated 14-gauge needle and with the 14-gauge directional vacuum-assisted device.
-
atypical Ductal hyperplasia and Ductal Carcinoma in situ as revealed by large core needle breast biopsy results of surgical excision
American Journal of Roentgenology, 2000Co-Authors: Marla Rosenfield L Darling, Carolyn M Kaelin, Darrell N Smith, Donnalee G Selland, C M Denison, Pamela J Dipiro, David I Rose, Esther Rhei, Susan C Lester, J E MeyerAbstract:OBJECTIVE. This investigation compares the frequency of histologic underestimation of breast Carcinoma that occurs when a large-core needle biopsy reveals atypical Ductal hyperplasia or Ductal Carcinoma in situ with the automated 14-gauge needle, the 14-gauge directional vacuum-assisted biopsy device, and the 11-gauge directional vacuum-assisted biopsy device.SUBJECTS AND METHODS. Evaluation of 428 large-core needle biopsies yielding atypical Ductal hyperplasia (139 lesions) or Ductal Carcinoma in situ (289 lesions) was performed. The results of subsequent surgical excision were retrospectively compared with the needle biopsy results.RESULTS. For lesions initially diagnosed as Ductal Carcinoma in situ, underestimation of invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device when compared with the automated 14-gauge needle (10% versus 21%, p < 0.05) but was not significantly less frequent when compared with the 14-gauge directional vacuum-ass...
Carolyn M Kaelin - One of the best experts on this subject based on the ideXlab platform.
-
Ductal Carcinoma in situ of the breast
The New England Journal of Medicine, 2004Co-Authors: Harold J. Burstein, Julia S Wong, Susan V. Lester, Kornelia Polyak, Carolyn M KaelinAbstract:Ductal Carcinoma in situ of the breast (also called intraDuctal Carcinoma), a clonal proliferation of malignant-appearing cells within the mammary duct lumens without evidence of invasion beyond the epithelial basement membrane, is the precursor lesion of invasive breast cancer. In the past 20 years, concomitant with the wide use of screening mammography, its detected incidence has risen dramatically. Data from large cohort studies and randomized trials have emerged to guide treatment. This review summarizes progress in the understanding, pathogenesis, and treatment of Ductal Carcinoma in situ.
-
atypical Ductal hyperplasia and Ductal Carcinoma in situ as revealed by large core needle breast biopsy results of surgical excision
American Journal of Roentgenology, 2000Co-Authors: Marla Rosenfield L Darling, Carolyn M Kaelin, Susan V. Lester, Darrell N Smith, Donnalee G Selland, C M Denison, Pamela J Dipiro, David I Rose, Esther Rhei, J E MeyerAbstract:OBJECTIVE: This investigation compares the frequency of histologic underestimation of breast Carcinoma that occurs when a large-core needle biopsy reveals atypical Ductal hyperplasia or Ductal Carcinoma in situ with the automated 14-gauge needle, the 14-gauge directional vacuum-assisted biopsy device, and the 11-gauge directional vacuum-assisted biopsy device. SUBJECTS AND METHODS: Evaluation of 428 large-core needle biopsies yielding atypical Ductal hyperplasia (139 lesions) or Ductal Carcinoma in situ (289 lesions) was performed. The results of subsequent surgical excision were retrospectively compared with the needle biopsy results. RESULTS: For lesions initially diagnosed as Ductal Carcinoma in situ, underestimation of invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device when compared with the automated 14-gauge needle (10% versus 21%, p 0.1). For lesions diagnosed initially as atypical Ductal hyperplasia, underestimation of Ductal Carcinoma in situ and invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device compared with the 14-gauge directional vacuum-assisted device (19% versus 39%, p = 0. 025) and with the automated 14-gauge needle (19% versus 44%, p = 0. 01). CONCLUSION: The frequency of histologic underestimation of breast Carcinoma in lesions initially diagnosed as atypical Ductal hyperplasia or Ductal Carcinoma in situ using large-core needle biopsy is substantially lower with the 11-gauge directional vacuum-assisted device than with the automated 14-gauge needle and with the 14-gauge directional vacuum-assisted device.
-
atypical Ductal hyperplasia and Ductal Carcinoma in situ as revealed by large core needle breast biopsy results of surgical excision
American Journal of Roentgenology, 2000Co-Authors: Marla Rosenfield L Darling, Carolyn M Kaelin, Darrell N Smith, Donnalee G Selland, C M Denison, Pamela J Dipiro, David I Rose, Esther Rhei, Susan C Lester, J E MeyerAbstract:OBJECTIVE. This investigation compares the frequency of histologic underestimation of breast Carcinoma that occurs when a large-core needle biopsy reveals atypical Ductal hyperplasia or Ductal Carcinoma in situ with the automated 14-gauge needle, the 14-gauge directional vacuum-assisted biopsy device, and the 11-gauge directional vacuum-assisted biopsy device.SUBJECTS AND METHODS. Evaluation of 428 large-core needle biopsies yielding atypical Ductal hyperplasia (139 lesions) or Ductal Carcinoma in situ (289 lesions) was performed. The results of subsequent surgical excision were retrospectively compared with the needle biopsy results.RESULTS. For lesions initially diagnosed as Ductal Carcinoma in situ, underestimation of invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device when compared with the automated 14-gauge needle (10% versus 21%, p < 0.05) but was not significantly less frequent when compared with the 14-gauge directional vacuum-ass...
Marla Rosenfield L Darling - One of the best experts on this subject based on the ideXlab platform.
-
atypical Ductal hyperplasia and Ductal Carcinoma in situ as revealed by large core needle breast biopsy results of surgical excision
American Journal of Roentgenology, 2000Co-Authors: Marla Rosenfield L Darling, Carolyn M Kaelin, Susan V. Lester, Darrell N Smith, Donnalee G Selland, C M Denison, Pamela J Dipiro, David I Rose, Esther Rhei, J E MeyerAbstract:OBJECTIVE: This investigation compares the frequency of histologic underestimation of breast Carcinoma that occurs when a large-core needle biopsy reveals atypical Ductal hyperplasia or Ductal Carcinoma in situ with the automated 14-gauge needle, the 14-gauge directional vacuum-assisted biopsy device, and the 11-gauge directional vacuum-assisted biopsy device. SUBJECTS AND METHODS: Evaluation of 428 large-core needle biopsies yielding atypical Ductal hyperplasia (139 lesions) or Ductal Carcinoma in situ (289 lesions) was performed. The results of subsequent surgical excision were retrospectively compared with the needle biopsy results. RESULTS: For lesions initially diagnosed as Ductal Carcinoma in situ, underestimation of invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device when compared with the automated 14-gauge needle (10% versus 21%, p 0.1). For lesions diagnosed initially as atypical Ductal hyperplasia, underestimation of Ductal Carcinoma in situ and invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device compared with the 14-gauge directional vacuum-assisted device (19% versus 39%, p = 0. 025) and with the automated 14-gauge needle (19% versus 44%, p = 0. 01). CONCLUSION: The frequency of histologic underestimation of breast Carcinoma in lesions initially diagnosed as atypical Ductal hyperplasia or Ductal Carcinoma in situ using large-core needle biopsy is substantially lower with the 11-gauge directional vacuum-assisted device than with the automated 14-gauge needle and with the 14-gauge directional vacuum-assisted device.
-
atypical Ductal hyperplasia and Ductal Carcinoma in situ as revealed by large core needle breast biopsy results of surgical excision
American Journal of Roentgenology, 2000Co-Authors: Marla Rosenfield L Darling, Carolyn M Kaelin, Darrell N Smith, Donnalee G Selland, C M Denison, Pamela J Dipiro, David I Rose, Esther Rhei, Susan C Lester, J E MeyerAbstract:OBJECTIVE. This investigation compares the frequency of histologic underestimation of breast Carcinoma that occurs when a large-core needle biopsy reveals atypical Ductal hyperplasia or Ductal Carcinoma in situ with the automated 14-gauge needle, the 14-gauge directional vacuum-assisted biopsy device, and the 11-gauge directional vacuum-assisted biopsy device.SUBJECTS AND METHODS. Evaluation of 428 large-core needle biopsies yielding atypical Ductal hyperplasia (139 lesions) or Ductal Carcinoma in situ (289 lesions) was performed. The results of subsequent surgical excision were retrospectively compared with the needle biopsy results.RESULTS. For lesions initially diagnosed as Ductal Carcinoma in situ, underestimation of invasive Ductal Carcinoma was significantly less frequent using the 11-gauge directional vacuum-assisted biopsy device when compared with the automated 14-gauge needle (10% versus 21%, p < 0.05) but was not significantly less frequent when compared with the 14-gauge directional vacuum-ass...
F Burbank - One of the best experts on this subject based on the ideXlab platform.
-
stereotactic breast biopsy of atypical Ductal hyperplasia and Ductal Carcinoma in situ lesions improved accuracy with directional vacuum assisted biopsy
Radiology, 1997Co-Authors: F BurbankAbstract:PURPOSE: To evaluate stereotactic, percutaneous, directional, vacuum-assisted breast biopsy of atypical Ductal hyperplasia (ADH) and Ductal Carcinoma in situ (DCIS). MATERIALS AND METHODS: Percutaneous biopsy was followed by surgical excision in 113 ADH and DCIS lesions in 101 patients (mean age, 55.5 years). Fourteen-gauge, automated needle biopsy was performed in 73 of these 113 lesions; 14-gauge, directional, vacuum-assisted breast biopsy was performed in 40 lesions. RESULTS: Eight of 18 lesions diagnosed with automated needle biopsy as ADH were determined at surgery to be breast cancer (DCIS or infiltrating Ductal Carcinoma). None of the eight ADH lesions diagnosed with directional, vacuum-assisted biopsy was determined at surgery to be breast cancer (P = .03, Fisher exact test). Nine of 55 lesions diagnosed with automated needle biopsy as DCIS were diagnosed as infiltrating Ductal Carcinoma at surgery. None of the 32 DCIS lesions diagnosed with directional, vacuum-assisted biopsy was diagnosed as infiltrating Ductal Carcinoma at surgery (P = .02, Fisher exact test). CONCLUSION: Directional, vacuum-assisted biopsy resulted in statistically significantly fewer cases of ADH or DCIS underestimation of disease without clinical complications or the creation of postbiopsy mammographic lesions.
-
stereotactic breast biopsy of atypical Ductal hyperplasia and Ductal Carcinoma in situ lesions improved accuracy with directional vacuum assisted biopsy
Radiology, 1997Co-Authors: F BurbankAbstract:PURPOSE: To evaluate stereotactic, percutaneous, directional, vacuum-assisted breast biopsy of atypical Ductal hyperplasia (ADH) and Ductal Carcinoma in situ (DCIS). MATERIALS AND METHODS: Percutaneous biopsy was followed by surgical excision in 113 ADH and DCIS lesions in 101 patients (mean age, 55.5 years). Fourteen-gauge, automated needle biopsy was performed in 73 of these 113 lesions; 14-gauge, directional, vacuum-assisted breast biopsy was performed in 40 lesions. RESULTS: Eight of 18 lesions diagnosed with automated needle biopsy as ADH were determined at surgery to be breast cancer (DCIS or infiltrating Ductal Carcinoma). None of the eight ADH lesions diagnosed with directional, vacuum-assisted biopsy was determined at surgery to be breast cancer (P = .03, Fisher exact test). Nine of 55 lesions diagnosed with automated needle biopsy as DCIS were diagnosed as infiltrating Ductal Carcinoma at surgery. None of the 32 DCIS lesions diagnosed with directional, vacuum-assisted biopsy was diagnosed as inf...
Christophe Goncalves - One of the best experts on this subject based on the ideXlab platform.
-
mnk1 nodal signaling promotes invasive progression of breast Ductal Carcinoma in situ
Cancer Research, 2019Co-Authors: Qianyu Guo, Jessica N Nichol, Fan Huang, William Yang, Samuel E J Preston, Zahra Talat, Hanne Lefrere, Guihua Zhang, Mark Basik, Christophe GoncalvesAbstract:The mechanisms by which breast cancers progress from relatively indolent Ductal Carcinoma in situ (DCIS) to invasive Ductal Carcinoma (IDC) are not well understood. However, this process is critical to the acquisition of metastatic potential. MAPK-interacting serine/threonine-protein kinase 1 (MNK1) signaling can promote cell invasion. NODAL, a morphogen essential for embryogenic patterning, is often reexpressed in breast cancer. Here we describe a MNK1/NODAL signaling axis that promotes DCIS progression to IDC. We generated MNK1 knockout (KO) or constitutively active MNK1 (caMNK1)-expressing human MCF-10A-derived DCIS cell lines, which were orthotopically injected into the mammary glands of mice. Loss of MNK1 repressed NODAL expression, inhibited DCIS to IDC conversion, and decreased tumor relapse and metastasis. Conversely, caMNK1 induced NODAL expression and promoted IDC. The MNK1/NODAL axis promoted cancer stem cell properties and invasion in vitro. The MNK1/2 inhibitor SEL201 blocked DCIS progression to invasive disease in vivo. In clinical samples, IDC and DCIS with microinvasion expressed higher levels of phospho-MNK1 and NODAL versus low-grade (invasion-free) DCIS. Cumulatively, our data support further development of MNK1 inhibitors as therapeutics for preventing invasive disease. SIGNIFICANCE: These findings provide new mechanistic insight into progression of Ductal Carcinoma and support clinical application of MNK1 inhibitors to delay progression of indolent Ductal Carcinoma in situ to invasive Ductal Carcinoma.
